Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study

Introduction: Patients with advanced non-small cell lung cancer (NSCLC) who progress after chemotherapy and immune checkpoint inhibitors (ICIs) need effective second-line treatments. The combination of nintedanib and docetaxel has shown promise, particularly post-ICI progression. This study evaluate...

Full description

Saved in:
Bibliographic Details
Main Authors: Natalia Fernández Núñez, Martín Lázaro Quintela, Jorge García González, Francisco Javier Afonso Afonso, María Carmen Areses Manrique, Cristina Azpitarte Raposeiras, Joaquin Mosquera Martinez, Lucia Santomé Couto
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Non–small cell lung cancer
Nintedanib
Docetaxel
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225000991
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294225000991

Similar Items